Last reviewed · How we verify
A Phase III, Randomized, Single-Blind, Superiority Study Comparing The Efficacy And Tolerability Of A New Drug Containing The Combination Meloxicam And Cyclobenzaprine And The Same Components Alone In The Treatment Of Acute Lumbago
The purpose of this study is to assess the efficacy end tolerability of a new drug containing the combination meloxicam and cyclobenzaprine (7,5/10mg) and the same components alone in the treatment of acute lumbago.
Details
| Lead sponsor | Eurofarma Laboratorios S.A. |
|---|---|
| Phase | Phase 3 |
| Status | WITHDRAWN |
| Start date | 2013-05 |
| Completion | 2013-05 |
Conditions
- Acute Lumbago
Interventions
- meloxicam/cyclobenzaprine hydrochloride
- meloxicam - Movatec®
- cyclobenzaprine - Miosan®
Primary outcomes
- Pain Reduction — Pain reduction 3 days after the administration of study drugs
Compare the treatment groups for the efficacy in pain reduction, 3 days after the administration of study drugs, when compared to the baseline assessment.
Countries
Brazil